AVADEL PHARMACEUTICALS - COM (AVDL)

Historical Holders from Q4 2016 to Q3 2025

Type / Class: Equity / COM
Symbol: AVDL on Nasdaq
Price per share: $15.27
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares as of 30 Sep 2025: 737,501
Total reported value: $11,261,641
Share change: 0
Number of holders: 3

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

As of 30 Sep 2025, AVADEL PHARMACEUTICALS - COM (AVDL) has 3 institutional shareholders filing 13F forms. They hold 737,501 shares. .

Institutional Holders of AVADEL PHARMACEUTICALS - COM (AVDL) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (% of par)	Investors
2025 Q3	737,501	$11,261,641			$0	1,527%	3
2025 Q2	737,501	$6,526,891			$215,475	885%	3
2025 Q1	737,501	$5,774,641	+$3,915			783%	3
2024 Q4	737,001	$7,745,886	-$4,367,129			1,051%	3
2024 Q3	1,070,001	$14,032,886	-$83,726,146			1,311.5%	5
2024 Q2	7,025,014	$98,771,327	-$1,036,586,640	$0	$0	1,406%	10
2024 Q1	67,722,533	$1,143,897,781	+$208,583,662	$34,279,944	$16,825,818	1,689%	121
2023 Q4	19,912	$281,157	-$475,265			1,412%	1
2023 Q3	53,840,366	$554,583,076	-$2,768,794	$3,010,690	$7,887,740	1,030%	95
2023 Q2	51,492,222	$848,604,177	+$73,277,101	$10,166,376	$11,691,712	1,648%	98
2023 Q1	48,371,490	$443,036,185	+$137,994,249	$4,475,576	$13,762,824	916%	88
2022 Q4	33,455,552	$239,492,674	+$16,217,340	$8,356,116	$10,391,328	716%	83
2022 Q3	31,382,376	$157,239,505	-$10,630,387	$6,324,000	$3,971,000	501%	72
2022 Q2	33,734,094	$82,308,348	-$28,507,344	$2,235,000	$2,578,000	244%	75
2022 Q1	35,805,427	$244,542,225	+$7,001,576	$2,281,000	$4,883,000	683%	76
2021 Q4	34,864,629	$281,718,295	+$3,984,190	$3,562,552	$5,910,000	808%	78
2021 Q3	32,066,701	$314,225,653	-$2,632,863	$1,584,800	$14,101,680	980%	81
2021 Q2	32,552,132	$219,088,519	-$1,445,645	$1,585,730	$2,990,033	673%	79
2021 Q1	32,624,275	$294,399,454	+$1,571,170	$2,641,000	$2,590,000	903.96%	77
2020 Q4	32,022,122	$213,943,593	+$3,570,784	$1,058,000	$846,000	668.02%	78
2020 Q3	31,489,502	$158,737,854	-$40,676,724	$812,000	$1,035,000	503.99%	76
2020 Q2	36,267,155	$293,030,910	+$72,708,094	$2,990,000	$3,432,000	807.98%	72
2020 Q1	26,839,702	$211,145,000	+$56,683,867	$2,829,000	$23,455,000	793.98%	53
2019 Q4	18,244,413	$137,742,000	+$2,567,714	$1,376,000	$1,476,000	754.98%	42
2019 Q3	19,368,854	$80,575,000	+$347,478	$239,000	$308,000	415.98%	39
2019 Q2	19,319,440	$55,832,000	-$530,738	$92,000		288.98%	39
2019 Q1	19,575,523	$28,191,000	-$905,815	$0		144%	36
2018 Q4	19,744,561	$50,896,000	-$1,392,366	$54,000	$0	257.97%	46
2018 Q3	20,130,519	$88,363,000	-$2,836,965	$270,000	$160,000	438.98%	60
2018 Q2	20,572,581	$126,110,065	-$36,190,040	$553,000	$364,000	613.01%	66
2018 Q1	25,861,666	$188,525,000	-$4,818,388	$831,000	$597,000	729%	71
2017 Q4	25,787,593	$211,448,000	-$16,854,007	$388,000		819.99%	73
2017 Q3	27,149,143	$284,285,000	-$5,516,082	$279,000		1,049.98%	77
2017 Q2	26,131,042	$288,224,000	+$21,561,742		$0	1,103.01%	72
2017 Q1	26,582,727	$257,486,000	+$215,656,341		$131,000	968%	67
2016 Q4	4,300,449	$44,678,000	+$44,677,983			1,039.11%	6